BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Anat Loewenstein, MD, MHA, speaks about 4D-150, a novel intravitreally administered gene therapy for wet age-related macular degeneration.
“We all like genetic treatment that is given intravitreally and does not necessitate subretinal therapy,” she said.
In the phase 2 PRISM trial, a single injection of 4D-150 (4D Molecular Therapeutics) given to patients previously treated with multiple anti-VEGF injections was able to reduce the treatment burden by almost 90%.
“It is very promising for our